Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953799 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2PKMKMT2AALDH1A1HPGD | |
| SCHEMBL1247252 | 0.81 | PKM (0.56) | SMN1; SMN2PKMKMT2AALDH1A1MAPT | |
| SCHEMBL11620684 | 0.81 | ALDH1A1 (0.58) | SMN1; SMN2PKMKMT2AALDH1A1HPGD | |
| SCHEMBL6988984 | 0.80 | MAPT (0.41) | SMN1; SMN2KMT2AALDH1A1MAPTNPSR1 | |
| SCHEMBL9793680 | 0.79 | POLB (0.50) | SMN1; SMN2PKMKMT2AALDH1A1HPGD | |
| SCHEMBL2656516 | 0.79 | POLB (0.50) | SMN1; SMN2PKMKMT2AALDH1A1HPGD | |
| SCHEMBL5369486 | 0.78 | KMT2A (0.50) | SMN1; SMN2KMT2AALDH1A1MAPTHTT | |
| SCHEMBL14540415 | 0.78 | RORC (0.46) | SMN1; SMN2PKMKMT2AALDH1A1HPGD | |
| SCHEMBL29745000 | 0.76 | ALDH1A1 (0.48) | SMN1; SMN2PKMKMT2AALDH1A1HPGD | |
| SCHEMBL505209 | 0.76 | ALDH1A1 (0.48) | SMN1; SMN2PKMKMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021435-B2 | Serotonin receptor-targeting compounds and methods | NORTHEASTERN UNIVERSITY (US) | 2021-06-01 | — | — | US | disclosed |
| US-10548856-B2 | Compounds and methods for modulating serotonin receptors in the periphery | NORTHEASTERN UNIVERSITY (US) | 2020-02-04 | — | — | US | disclosed |
| US-20180125798-A1 | Compounds and Methods for Modulating Serotonin Receptors in the Periphery | NORTHEASTERN UNIVERSITY | 2018-05-10 | — | — | US | disclosed |
| US-20180125798-A1 | Compounds and Methods for Modulating Serotonin Receptors in the Periphery | NORTHEASTERN UNIVERSITY | 2018-05-10 | — | — | US | disclosed |
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170081273-A1 | Serotonin Receptor-Targeting Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-23 | — | — | US | disclosed |
| US-20170081273-A1 | Serotonin Receptor-Targeting Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-23 | — | — | US | disclosed |
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20140309216-A1 | PHARMACEUTICAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-16 | — | — | US | disclosed |
| US-8802670-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2014-08-12 | — | — | US | disclosed |
| US-7893063-B2 | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer | ASTRAZENECA AB (SE) | 2011-02-22 | — | — | US | disclosed |
| US-20100009959-A1 | Pentacyclic Indole Derivatives as Antiviral Agents | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-01-14 | — | — | US | disclosed |
| US-20090143384-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | ASTRAZENECA UK LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| EP-2041139-A2 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-01 | — | — | EP | disclosed |
| EP-2027125-A1 | PENTACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-02-25 | — | — | EP | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
| WO-2007129119-A1 | PENTACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007127175-A2 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-08 | — | — | WO | disclosed |
| EP-1773824-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006005915-A1 | 2, 4, 6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125798-A1 | Compounds and Methods for Modulating Serotonin Receptors in the Periphery | HTR5A, HTR3A, HTR1A | SMN1; SMN2 1984/4885PKM 1885/4885KMT2A 3180/4885 |
| US-20100009959-A1 | Pentacyclic Indole Derivatives as Antiviral Agents | IDO1, IDO2, ZC3HAV1 | SMN1; SMN2 4827/4885PKM 3012/4885KMT2A 3311/4885 |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIK3CA, PIK3CD, PIK3CB | SMN1; SMN2 1733/4885PKM 738/4885KMT2A 964/4885 |
| US-20140309216-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, AKT3 | SMN1; SMN2 1704/4885PKM 162/4885KMT2A 4014/4885 |
| US-10548856-B2 | Compounds and methods for modulating serotonin receptors in the periphery | HTR5A, HTR3A, HTR1A | SMN1; SMN2 1984/4885PKM 1885/4885KMT2A 3180/4885 |
| US-20090143384-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | PIK3CA, PIK3CB, TYMP | SMN1; SMN2 3873/4885PKM 818/4885KMT2A 1852/4885 |
| US-11021435-B2 | Serotonin receptor-targeting compounds and methods | HTR1A, HTR2C, HTR7 | SMN1; SMN2 1243/4885PKM 3389/4885KMT2A 1801/4885 |
| US-20170081273-A1 | Serotonin Receptor-Targeting Compounds and Methods | HTR1A, HTR2C, HTR7 | SMN1; SMN2 1243/4885PKM 3389/4885KMT2A 1801/4885 |
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, AKT3 | SMN1; SMN2 1704/4885PKM 162/4885KMT2A 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.